title: Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.
abstract: OBJECTIVE
  The purpose of this study was to determine whether bisphosphonate treatment can prevent or delay osteocyte apoptosis in a cyclic fatigue animal model and if there are differences between two different bisphosphonates in their effects on osteocyte apoptosis.
  
  
  BACKGROUND
  Fatigue loading induces microdamage in long bones in rats and causes osteocyte apoptosis. In vitro data suggest that the bisphosphonates can prevent osteocyte apoptosis.
  
  
  METHODS
  Six month old female Sprague-Dawley rats (n=72) were given a daily subcutaneous (sc) injection of saline vehicle, risedronate (RIS: 0.05 mug/kg per day) or alendronate (ALN: 0.1 mug/kg per day). On the 8th day of drug treatment, an axial compressive load was applied to the right ulna using a load-controlled electromagnetic device (17N, 6000 cycles, 2 Hz, 10% loss of stiffness approximately 1 h). Three, seven or ten days after loading, the animals were sacrificed. Immunohistochemistry for caspase-3 was performed to assess the extent of osteocyte apoptosis in loaded and non-loaded ulnas.
  
  
  RESULTS
  Microdamage (Mdx) created by cyclic loading of the ulna induced a significant increase (p=0.03) in the number of apoptotic osteocytes compared to non-damaged regions of the same ulna, and compared to the contralateral non-loaded ulna. Risedronate and alendronate had an early effect (3 days after loading) on reducing load-induced osteocyte apoptosis. Risedronate significantly reduced the density of apoptotic osteocytes compared to vehicle-treated controls by approximately 50% in the Mdx area, whereas alendronate reduced it by approximately 40%. There were no differences among groups by seven days following loading.
  
  
  CONCLUSIONS
  (1) Low doses of risedronate or alendronate suppressed osteocyte apoptosis induced by fatigue loading of the ulna in rats. (2) There was no difference between the effects of risedronate or alendronate on osteocyte apoptosis at these doses.
authors.affiliation: Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. helene.follet@sante.univ-lyon1.fr
authors.forename: Helene
authors.initials: H
authors.lastname: Follet
authors.forename: Jiliang
authors.initials: J
authors.lastname: Li
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Phipps
authors.forename: Siu
authors.initials: S
authors.lastname: Hui
authors.forename: Keith
authors.initials: K
authors.lastname: Condon
authors.forename: David B
authors.initials: DB
authors.lastname: Burr
mesh_terms: D019386:Alendronate / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001696:Biomechanical Phenomena; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D010011:Osteocytes / Q000166:cytology* / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D000068296:Risedronic Acid; D013314:Stress, Mechanical; D014457:Ulna / Q000166:cytology / Q000187:drug effects / Q000502:physiology
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate